First Wave BioPharma Forms Clinical Steering Committee Focused on Advancing Inflammatory Bowel Disease (IBD) Product Portfolio
27 avr. 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 27, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Europe Animal Healthcare Market revenue to surpass $49.4bn by 2027, says Graphical Research
26 avr. 2022 03h12 HE
|
Graphical Research
Pune, India, April 26, 2022 (GLOBE NEWSWIRE) -- As per a recent industry report put forward by Graphical Research, the Europe animal healthcare market is forecast to register its name in the...
Aquaculture Healthcare Market to cross $1.25 billion by 2028, Says Global Market Insights Inc.
02 févr. 2022 03h35 HE
|
Global Market Insights Inc.
Selbyville, Delaware, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Global aquaculture healthcare market revenue is projected to cross USD 1.25 billion by 2028, according to a new research report by Global...
First Wave BioPharma to Participate in Two Investor Conferences in January 2022
04 janv. 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 04, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium
29 oct. 2021 15h44 HE
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases...
First Wave BioPharma Announces Dosing of First Patient in Phase 2b Clinical Trial Evaluating Topical Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis
14 oct. 2021 09h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 14, 2021 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Linalool Market Size to Reach $696.2 Million by 2030 | CAGR: 4.2%: AMR
12 oct. 2021 04h04 HE
|
Allied Market Research
Portland, OR, Oct. 12, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global linalool market was estimated at 462.6 million in 2020 and is expected to hit...
ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19
16 sept. 2021 08h30 HE
|
ARCA biopharma, Inc.
First international patient enrolled in BrazilTrial approximately 75% enrolledrNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patientsTopline trial data anticipated in...
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
13 sept. 2021 06h00 HE
|
AzurRx BioPharma, Inc.
AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI” Three IBD clinical indications, including ulcerative colitis and Crohn’s disease, added to GI...
AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis
08 sept. 2021 08h30 HE
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...